Issue image

Online ISSN:
2831-090X

ISSN:
2831-0896

Volume 23 , Issue 2, (2023)

Published:
11.07.2023.

Open Access

Powered by

Opus logo

Advanced online

This is just one article to demostrate article based workflow. 

Authors in this issue:

Jovanovic, Armin Hajdic, Biomol Biomed, Hastono Ridwansyah,

11.03.2023.

Research article

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review

B-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affecting certain genes, contribute to relapses and refractory cases. Chidamide (tucidinostat) is a novel histone deacetylase inhibitor that can reverse this epigenetic imbalance and has been approved for the treatment of T-cell malignancies. However, the use of chidamide for B-NHL remains limited, and the lack of relevant literature exacerbates this limitation. We conducted this review to summarize the anticancer activity of chidamide against B-NHL and its clinical applications to overcome drug resistance. This systematic review was conducted according to the PRISMA 2020 guidelines, using some keyword combinations from MEDLINE and EBSCO. The inclusion and exclusion criteria were also defined. Of the 131 records retrieved from databases, 16 were included in the review. Nine articles revealed that chidamide limited tumor progression by modifying the tumor microenvironment, stopping the cell cycle, inducing apoptosis and autophagy, and enhancing complement-dependent and antibody-dependent cell-mediated cytotoxicities.According to seven other studies, administering chidamide in combination with another existing therapeutic regimen may benefit not only patients with relapsed/refractory B-NHL, but also those with newly diagnosed B-NHL. Chidamide plays many important roles in limiting B-NHL progression through epigenetic modifications. Thus, combining chidamide with other anticancer drugs may be more beneficial for patients with newly diagnosed and relapsed/refractory B-NHL.

Hastono Ridwansyah

31.05.2024.

Review paper

Corrigendum: IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation

This corrigendum corrects the authorship information to: Yipeng Xu, Gabriela Pachnikova, He Wang, Yaoyao Wu, Dorothea Przybilla, Zihao Chen, Shaoxing Zhu, Ulrich Keilholz. At the request of Dr. Reinhold Schäfer and with the agreement of all authors, Dr. Reinhold Schäfer is excluded from the list of authors. Dr. Schäfer expresses no doubts about the article's results and conclusion but was erroneously included on the list of authors.

 

The authors sincerely apologize for the error and confirm that this correction does not change the conclusion of the article.

Biomol Biomed

15.03.2024.

Research article

Changes in the Location and Meaning of Banjalukaโ€™s Urban Core: Recommendations for Urban Landscape Regeneration

The starting premise of this paper is that a careful interpretation of changes in the meaning of urban places, provided their autochthonous qualities and the quality of the urban environment and architecture are respected, can help to better understand and treat the built environment. The case study presented investigates Banja Luka’s urban landscape, i.e.concrete changes to its urban core and the principles that have underlain its planning and construction over time. Also, it shows how the use of different regulation instruments and the formation of spatial hierarchies led to spatial-physical, visual, and symbolic or axiological-normative properties, as well as standards of use, translating into features of spatial identity. 

Jovanovic, Armin Hajdic

ABSTRACTING AND INDEXING

The BJBMS Journal is included to all relevant abstract and citation databases. For a full list visit About page. These include (but are not limited to):

Partners